9 results about "Post stroke" patented technology

The present invention relates to a biomarker composition for diagnosing stroke or post-stroke neurological damage, for diagnosing the severity of stroke or post-stroke neurological damage, and for predicting stroke prognosis, and the like. Using an ischemic stroke mouse disease model, a tissue damage analysis and a behavioral analysis were performed, and the mRNA level expression was confirmed, and as a result, Prox1 or Dcx could be selected as a biomarker. In addition, it was confirmed that the expression of Prox1 or Dcx increased as the severity of stroke or post-stroke neurological damage was higher, and thus the present invention is expected to be useful for diagnosing stroke or post-stroke neurological damage, for diagnosing the severity of stroke or post-stroke neurological damage, and for predicting stroke prognosis.

Extracellular vesicles and / or exosomes (EVs) remain sparsely studied in hemorrhagic transformations, including stroke and intracranial hemorrhages and could provide key insights into stroke pathophysiology. We assessed plasma levels of neuron-derived EVs (NDEs), astrocyte-derived EVs (ADEs), and oligodendrocyte-derived EVs (ODEs) in 58 patients 5, 15, and 30 days post-ischemic stroke along with 46 matched controls using sandwich immunoassays. Hemorrhagic transformation was a better predictor of ADE levels than lesion volume in linear regression models. These findings suggest that ADE levels are preferentially increased over the first month post-stroke compared to EVs from other neural cell types. ADEs may be of additional interest as biomarkers of blood-brain barrier breakdown to predict hemorrhagic transformation at earlier time points after stroke.

The application discloses a tail suspension test device and method for evaluating the behavioral despair of mice after stroke, wherein a slope plate is arranged below the hanging piece for hanging the mice in the hanging chamber, so as to prevent the mice from struggling due to movement coordination disorders, to help the suspended mice keep balance, and to prevent the mice from shaking even if the movement ability of the mice is impaired, and the application is particularly suitable for evaluating the despair of the mice with impaired movement coordination after stroke. The application supports part of the body weight of the mice through the slope plate, the pain caused during the test is slight, and the application can also be used for rats once the size of the device is adapted to the rats. The application is a modified detection method (mTST for short) of TST, and is used for evaluating the behavioral despair of the mice after stroke. The application can be applied to the evaluation of the curative effect of antidepressant drugs on the model mice of chronic mild stress (CMS) and post-stroke depression (PSD), and is favorable to the basic research of diseases such as PSD and the clinical transformation of drugs.

The invention relates to a traditional Chinese medicine composition for preventing constipation after stroke, an application and a preparation method thereof. The traditional Chinese medicine composition is prepared from the following raw materials in parts by weight: 12 to 15 parts of fructus aurantii, 9 to 12 parts of radix aucklandiae, 10 to 15 parts of fructus akebiae, 6 to 8 parts of cassia twig, 10 to 12 parts of vinegar rhizoma cyperi, 6 to 8 parts of rhizoma zingiberis, 10 to 15 parts of poria cocos and 3 to 5 parts of rhizoma cimicifugae. The traditional Chinese medicine composition disclosed by the invention is reasonable in compatibility, has the effects of relaxing bowel, warming yang, relaxing bowels, invigorating spleen, replenishing qi, ascending lucidity, descending turbid and the like, promotes the recovery of normal conduction functions of intestinal tracts, and effectively prevents the occurrence of early constipation of apoplexy patients.

The invention provides a method for processing biological signals generated in lower limb movement, which comprises the following steps of: preprocessing collected electroencephalogram signals and electromyographic signals which are generated corresponding to ankle dorsal flexion actions; calculating the cross spectrum density between the electroencephalogram signal and the electromyographic signal according to the preprocessed electroencephalogram signal and the preprocessed electromyographic signal; the coupling strength of the electroencephalogram signals and the electromyographic signals at the specific frequency is calculated according to the cross spectrum density, and the coupling strength is used for evaluating the lower limb movement function of the sporter. According to the invention, a frequency band specific normalized cross-spectrum power (NCSP) analysis method is adopted to quantify the coupling strength of the electroencephalogram signal and the electromyographic signal in alpha, beta and gamma frequency bands, a neural mechanism of coupling weakening of the alpha and beta frequency bands after stroke is disclosed, a new biomarker is provided for motion control disorder, and the application prospect is wide. And personalized rehabilitation evaluation and dynamic adjustment can be realized based on the dynamic change of the NCSP value, and formulation and optimization of a precise rehabilitation scheme are supported.

Astrocytes are known to regulate the body responses to diseases and injuries in central nervous system (CNS). Embodiments of the instant disclosure relate to biomaterial for delivering extracellular vesicles derived from reactive cell populations for improving brain healing after injury. Also provided are methods of improving angiogenesis, axonogenesis, or inducing tissue repair using the disclosed biomaterials. Also provided are methods of making the biomaterials.

Disclosed herein are methods of reducing or preventing cerebral edema in a subject after a stroke by administering systemically a therapeutically effective amount of a PD-1 agonist to the subject. Also disclosed herein are methods of treating neuroinflammation, improving gait, improving sensorimotor deficits, reducing the number of PD-1 positive monocytes in the brain, decreasing intracranial pressure, shifting the phenotype of monocytes in the brain from a classical inflammatory subtype to a non-classical subtype, and limiting or reducing secondary inflammatory injury, reducing a risk of a second or more stroke events in a subject after a stroke.

A method of predicting an effect of ischemic stroke on an individual's cognitive status comprises (1) acquiring at least one medical brain image of an individual's brain after the ischemic stroke of the individual; (2) processing the medical brain image to obtain at least one feature of the image; (3) generating a gray matter brain age (GMBA) value of the individual based on the at least one feature of the image; and (4) predicting an effect of the ischemic stroke on the individual's post-stroke cognitive status (PSCI) using the GMBA value.

Stroke is the primary cause of death and disability of residents in China, and research and development of breakthrough diagnosis and treatment strategies are extremely urgent due to aggravation of population aging. Current clinical treatment means are mainly limited to thrombolysis and the like, and a specific protection strategy for neuronal injury after stroke still has obvious defects. According to the invention, acetylation modification of 295th lysine (K295) of a mitochondrial apoptosis-inducing factor (AIF) is eliminated in a targeted manner by applying a specific deacetylase activator, abnormal translocation of the AIF from mitochondria to cell nucleus under ischemia stress is effectively inhibited, and a chromosome DNA fragmentation process mediated by the AIF is blocked, so that the programmed death level of neurons is remarkably reduced, and the application of the AIF in the preparation of the medicine for treating the neurons is realized. Therefore, the brain injury after the stroke is reduced. In cell and mouse stroke models, after K295 acetylation modification of the AIF is specifically eliminated, the neuron survival rate is increased by 4 times (plt, 0.01), and the cerebral infarction volume is reduced by 40% (plt, 0.01). The invention provides a brand-new drug action target and a treatment strategy for developing a post-stroke neuroprotection therapy.